Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 1/20 | 0.56 |
| ▸ | TRAP1 | Q12931 | 2/20 | 0.46 |
| ▸ | CHRNA7 | P36544 | 7/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.43 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL286882 | 1.00 | HIF1A (0.56) | HIF1ATRAP1CHRNA7ALDH1A1CYP1A2 | |
| Bromide SCHEMBL2446607 | 1.00 | HIF1A (0.56) | HIF1ATRAP1CHRNA7ALDH1A1CYP1A2 | |
| Bromide SCHEMBL678415 | 1.00 | HIF1A (0.56) | HIF1ATRAP1CHRNA7ALDH1A1CYP1A2 | |
| Bromide SCHEMBL362235 | 1.00 | HIF1A (0.56) | HIF1ATRAP1CHRNA7ALDH1A1CYP1A2 | |
| Bromide SCHEMBL1866839 | 1.00 | HIF1A (0.56) | HIF1ATRAP1CHRNA7ALDH1A1CYP1A2 | |
| Bromide SCHEMBL7759526 | 1.00 | HIF1A (0.56) | HIF1ATRAP1CHRNA7ALDH1A1CYP1A2 | |
| Bromide SCHEMBL635580 | 1.00 | HIF1A (0.56) | HIF1ATRAP1CHRNA7ALDH1A1CYP1A2 | |
| Bromide SCHEMBL164301 | 1.00 | HIF1A (0.56) | HIF1ATRAP1CHRNA7ALDH1A1CYP1A2 | |
| Bromide SCHEMBL2979400 | 1.00 | HIF1A (0.56) | HIF1ATRAP1CHRNA7ALDH1A1CYP1A2 | |
| Bromide SCHEMBL1963378 | 1.00 | HIF1A (0.56) | HIF1ATRAP1CHRNA7ALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10588962-B2 | Carbohydrate-glycolipid conjugate vaccines | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2020-03-17 | — | — | US | disclosed |
| US-10052373-B2 | Protein and peptide-free synthetic vaccines against Streptococcus pneumoniae type 3 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2018-08-21 | — | — | US | disclosed |
| EP-3046587-B1 | PROTEIN AND PEPTIDE-FREE SYNTHETIC VACCINES AGAINST STREPTOCOCCUS PNEUMONIAE TYPE 3 | MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WSS (DE) | 2018-01-31 | — | — | EP | disclosed |
| US-20160279224-A1 | PROTEIN AND PEPTIDE-FREE SYNTHETIC VACCINES AGAINST STREPTOCOCCUS PNEUMONIAE TYPE 3 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2016-09-29 | — | — | US | disclosed |
| EP-3046587-A1 | PROTEIN AND PEPTIDE-FREE SYNTHETIC VACCINES AGAINST STREPTOCOCCUS PNEUMONIAE TYPE 3 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften (DE) | 2016-07-27 | — | — | EP | disclosed |
| US-20150238597-A1 | CARBOHYDRATE-GLYCOLIPID CONJUGATE VACCINES | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2015-08-27 | — | — | US | disclosed |
| EP-2827899-B1 | POLYSACCHARIDE ANTIGEN-GLYCOLIPID CONJUGATE VACCINES | MAX PLANCK GES ZUR FÖRDERUNG DER WISSENSCHAFTEN E V (DE) | 2015-08-05 | — | — | EP | disclosed |
| WO-2015040140-A1 | PROTEIN AND PEPTIDE-FREE SYNTHETIC VACCINES AGAINST STREPTOCOCCUS PNEUMONIAE TYPE 3 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2015-03-26 | — | — | WO | disclosed |
| EP-2851092-A1 | Protein and peptide-free synthetic vaccines against streptococcus pneumoniae type 3 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2015-03-25 | — | — | EP | disclosed |
| EP-2827899-A1 | CARBOHYDRATE-GLYCOLIPID CONJUGATE VACCINES | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2015-01-28 | — | — | EP | disclosed |
| US-4968851-A | AGAINST ARTHROPODS AND NEMATODES | BAYER AKTIENGESELLSCHAFT (DE) | 1990-11-06 | — | — | US | disclosed |
| EP-0247484-B1 | HALOGEN OLEFINES | BAYER AG (DE) | 1990-08-16 | — | — | EP | disclosed |
| US-4839390-A | FOR SOIL TREATMENT; AGRICULTURE | BAYER AKTIENGESELLSCHAFT (DE) | 1989-06-13 | — | — | US | disclosed |
| US-4775662-A | ASTHMA TREATMENT, ANTIALLERGENS, BRONCHODILATOR AGENTS | SMITHKLINE BECKMAN CORPORATION (US) | 1988-10-04 | — | — | US | disclosed |
| EP-0248597-A2 | Phospholipase A2 inhibitors and methods of synthesis | ORTHO PHARMACEUTICAL CORPORATION (US) | 1987-12-09 | — | — | EP | disclosed |
| EP-0247484-A1 | Halogen olefines | BAYER AG (DE) | 1987-12-02 | — | — | EP | disclosed |
| EP-0121350-B1 | SUBSTITUTED UNSATURATED MERCAPTOCARBOXYLIC ACIDS AND DERIVATIVES AS LEUKOTRIENE ANTAGONISTS | SMITHKLINE BECKMAN CORPORATION (US) | 1987-05-13 | — | — | EP | disclosed |
| US-4533747-A | ANTIASTHMATICS, ANTIHISTAMINES | SMITHKLINE BECKMAN CORPORATION (US) | 1985-08-06 | — | — | US | disclosed |
| EP-0121350-A2 | Substituted unsaturated mercaptocarboxylic acids and derivatives as leukotriene antagonists | SMITHKLINE BECKMAN CORPORATION (US) | 1984-10-10 | — | — | EP | disclosed |
| US-4346040-A | Process for converting an aldehyde into an alkene, in particular furfural into furfurylidenes | AGRIFURANE S.A. (FR) | 1982-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150238597-A1 | CARBOHYDRATE-GLYCOLIPID CONJUGATE VACCINES | STT3B, STT3A, DDOST | HIF1A 4077/4885TRAP1 1937/4885CHRNA7 3808/4885 |
| US-10052373-B2 | Protein and peptide-free synthetic vaccines against Streptococcus pneumoniae type 3 | STT3A, DDOST, LGALS3BP | HIF1A 3156/4885TRAP1 2716/4885CHRNA7 3443/4885 |
| US-20160279224-A1 | PROTEIN AND PEPTIDE-FREE SYNTHETIC VACCINES AGAINST STREPTOCOCCUS PNEUMONIAE TYPE 3 | STT3A, DDOST, LGALS3BP | HIF1A 3156/4885TRAP1 2716/4885CHRNA7 3443/4885 |
| US-10588962-B2 | Carbohydrate-glycolipid conjugate vaccines | STT3B, STT3A, DDOST | HIF1A 4077/4885TRAP1 1937/4885CHRNA7 3808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.